New Molecular Insight to Breast and Ovarian Cancer

Disease relapse caused by drug resistance still represents a major clinical hurdle in cancer treatments. Breast and ovarian cancer cells may take advantage of different intracellular and genetic systems attenuating the drug effects. Resistant cells or minimal residual disease (MRD) cells have strong clinical relevance as they may give rise to secondary tumors when the therapy is concluded. Multifaced mechanisms like drug resistance, radioresistance, hypoxia, and growth factor deprivation are associated with a number of genes and signaling pathways that process the proliferation and cell death of breast and ovarian cancer cells. Reasons for resistance include extracellular matrix (ECM), ER stress, cancer-related fibroblasts, DNA damage oxidants, epithelial–mesenchyme transition, epigenetic modification, pathway activation, exosomes, autophagy, inflammatory immune cells, endocytosis, and so on. Moreover, identifying the molecular mechanisms and breast and ovarian cancer cells as new concepts involved in cancer therapy may potentially lead to new therapeutic targets. To solve tumor resistance, the relationship between the cell signaling pathway and tumor resistance models is significant for studying the mechanism for cell survival and cell death. New molecular insights into anti-breast and -ovarian cancer reagents, including natural products and new drugs, against breast and ovarian tumor resistance models are new advanced strategies to overcome resistance to cancer therapy, but the underlying mechanisms are not fully clarified.

This Special Issue will focus on the new advances in therapeutic strategies to overcome chemoresistance in breast and ovarian-resistant cancer models. Moreover, we will suggest progress in the understanding of various resistance breast and ovarian cancer types and focus on therapeutic approaches to develop new treatments to overcome chemoresistance.

Dr. Tae Woo Kim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• radiation
• hypoxia
• growth factor deprivation
• apoptosis
• autophagy
• epigenetics
• cell death
• cell survival
• resistance
• breast cancer
• ovarian cancer